These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

132 related articles for article (PubMed ID: 1650335)

  • 1. First clinical study of the selective 5-HT3 antagonist, granisetron (BRL 43694), in the acute treatment of migraine headache.
    Couturier EG; Hering R; Foster CA; Steiner TJ; Clifford Rose F
    Headache; 1991 May; 31(5):296-7. PubMed ID: 1650335
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Granisetron, a selective 5-HT3 receptor antagonist, for the prevention of radiation induced emesis during total body irradiation.
    Hunter AE; Prentice HG; Pothecary K; Coumar A; Collis C; Upward J; Murdoch R; Gandhi L; Hamon M; Butler M
    Bone Marrow Transplant; 1991 Jun; 7(6):439-41. PubMed ID: 1651794
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The serotonin type 3 receptor antagonist BRL 43694 and nausea and vomiting induced by cisplatin.
    Carmichael J; Cantwell BM; Edwards CM; Rapeport WG; Harris AL
    BMJ; 1988 Jul; 297(6641):110-1. PubMed ID: 2841996
    [No Abstract]   [Full Text] [Related]  

  • 4. A double-blind comparison of granisetron and placebo for the treatment of acute migraine in the emergency department.
    Rowat BM; Merrill CF; Davis A; South V
    Cephalalgia; 1991 Nov; 11(5):207-13. PubMed ID: 1663423
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [BRL 43694A--a 5-hydroxytryptamine receptor blocker as an antiemetic in cytostatic therapy].
    Joss R; Rohrbach D; Buser K; Pirovino M; Karde C; Brunner K
    Schweiz Med Wochenschr; 1989 Jun; 119(23):831-4. PubMed ID: 2549616
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Repeated use of granisetron in patients receiving cytostatic agents.
    de Wet M; Falkson G; Rapoport BL
    Cancer; 1993 Jun; 71(12):4043-9. PubMed ID: 8389659
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy and safety of granisetron in the prevention of chemotherapy-induced emesis in paediatric patients.
    Lemerle J; Amaral D; Southall DP; Upward J; Murdoch RD
    Eur J Cancer; 1991; 27(9):1081-3. PubMed ID: 1659848
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The 5-HT3 antagonist, BRL 43694, does not compromise the efficacy of cisplatin in tumour-bearing mice.
    Goddard PM; Jones M; Pollard LA; Valenti MR; Harrap KR
    Cancer Chemother Pharmacol; 1990; 25(5):377-9. PubMed ID: 2155065
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical studies with granisetron, a new 5-HT3 receptor antagonist for the treatment of cancer chemotherapy-induced emesis. The Granisetron Study Group.
    Joss RA; Dott CS
    Eur J Cancer; 1993; 29A Suppl 1():S22-9. PubMed ID: 8381293
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Granisetron. A review of its pharmacological properties and therapeutic use as an antiemetic.
    Plosker GL; Goa KL
    Drugs; 1991 Nov; 42(5):805-24. PubMed ID: 1723376
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A comparison of two dose levels of granisetron in patients receiving high-dose cisplatin. The Granisetron Study Group.
    Soukop M
    Eur J Cancer; 1990; 26 Suppl 1():S15-9. PubMed ID: 2169779
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A pharmacokinetic study of granisetron (BRL 43694A), a selective 5-HT3 receptor antagonist: correlation with anti-emetic response.
    Carmichael J; Cantwell BM; Edwards CM; Zussman BD; Thompson S; Rapeport WG; Harris AL
    Cancer Chemother Pharmacol; 1989; 24(1):45-9. PubMed ID: 2541937
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Who should receive a 5-HT3 antagonist?
    Kaye SB; Khayat D; Aapro M; Diehl V
    Lancet; 1992 Oct; 340(8827):1107-8. PubMed ID: 1357507
    [No Abstract]   [Full Text] [Related]  

  • 14. A comparison of two dose levels of granisetron in patients receiving moderately emetogenic cytostatic chemotherapy. The Granisetron Study Group.
    Smith IE
    Eur J Cancer; 1990; 26 Suppl 1():S19-23. PubMed ID: 2169780
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Recent developments in the management of emesis with the 5-HT3 antagonist granisetron.
    Button D
    Semin Oncol Nurs; 1990 Nov; 6(4 Suppl 1):14-9. PubMed ID: 2177568
    [No Abstract]   [Full Text] [Related]  

  • 16. A comparative study of the use of granisetron, a selective 5-HT3 antagonist, versus a standard anti-emetic regimen of chlorpromazine plus dexamethasone in the treatment of cytostatic-induced emesis. The Granisetron Study Group.
    Marty M
    Eur J Cancer; 1990; 26 Suppl 1():S28-32. PubMed ID: 2169783
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Zatosetron, a 5-HT3 receptor antagonist in a multicenter trial for acute migraine.
    Chappell AS; Bay JM; Botzum GD; Cohen ML
    Neuropharmacology; 1994; 33(3-4):509-13. PubMed ID: 7984290
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Phase I/II trial of granisetron: a novel 5-hydroxytryptamine antagonist for the prevention of chemotherapy-induced nausea and vomiting.
    Addelman M; Erlichman C; Fine S; Warr D; Murray C
    J Clin Oncol; 1990 Feb; 8(2):337-41. PubMed ID: 2153767
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Comparison of the antiemetic effectiveness of granisetron and alizapride plus dexamethasone in cytostatic therapy].
    Bremer K; Uhlenbusch R
    Dtsch Med Wochenschr; 1991 Nov; 116(48):1817-23. PubMed ID: 1659980
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Superiority of granisetron to dexamethasone plus prochlorperazine in the prevention of chemotherapy-induced emesis.
    Warr D; Willan A; Fine S; Wilson K; Davis A; Erlichman C; Rusthoven J; Lofters W; Osoba D; Laberge F
    J Natl Cancer Inst; 1991 Aug; 83(16):1169-73. PubMed ID: 1653363
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.